Inflammatory disorders

FDA approves Wezlana for multiple inflammatory diseases

The U.S. Food and Drug Administration has approved Amgen's Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.

Health

Oral health workers are burned out too, says report

Burnout is a prevalent problem for the health workforce, associated with employee turnover, absenteeism and depression. Burnout has also been shown to increase risk of medical errors and raises concerns about patient safety.

Genetics

3D genome architecture influences SCID-X1 gene therapy success

Patients with X-linked severe combined immunodeficiency disorder (SCID-X1), sometimes called "bubble boy disease," are born with a defective gene that prevents them from producing immune cells. Gene therapy from St. Jude ...

page 5 from 40